Taysha Gene Therapies (TSHA) Return on Capital Employed (QoQ) (2021 - 2026)

Taysha Gene Therapies (TSHA) Return on Capital Employed (QoQ) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Taysha Gene Therapies 2.14 Bn 2.14 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -751.00
Dec 31, 2025 -195.00
Sep 30, 2025 1,019.00
Jun 30, 2025 2,517.00
Mar 31, 2025 -635.00
Dec 31, 2024 -896.00
Sep 30, 2024 29.00
Jun 30, 2024 975.00
Mar 31, 2024 -1,545.00
Dec 31, 2023 -31,268.00
Sep 30, 2023 55,520.00
Jun 30, 2023 -7,417.00
Mar 31, 2023 7,219.00
Dec 31, 2022 -12,093.00
Sep 30, 2022 -378.00
Jun 30, 2022 -2,995.00
Mar 31, 2022 -3,642.00
Dec 31, 2021 -2,700.00
Sep 30, 2021 -2,192.00
Jun 30, 2021 -1,970.00